| Literature DB >> 15229791 |
David S Saperstein1, Richard J Barohn.
Abstract
Although once a severe and often fatal illness, myasthenia gravis can now be well managed with several relatively safe and effective therapies. Management involves a graded approach, beginning with cholinesterase inhibitors for mild symptoms and advancing to immunomodulating medications for more severe weakness. There are several immunomodulating agents from which to choose; selection is based largely on time to clinical effect and adverse effects. This review will discuss the selection and use of therapies for patients with myasthenia gravis.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15229791 DOI: 10.1055/s-2004-829586
Source DB: PubMed Journal: Semin Neurol ISSN: 0271-8235 Impact factor: 3.420